New medication also reduces by 40 percent the number of pulmonary exacerbations, the leading cause of death in cystic fibrosis patients Results from two phase 3 clinical trials published tod... Read more
New medication also reduces by 40 percent the number of pulmonary exacerbations, the leading cause of death in cystic fibrosis patients Results from two phase 3 clinical trials published tod... Read more
Copyright 2024. Created by Innovation Toronto